Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

doi:10.1038/s41591-018-0009-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Nature medicine - 1 May 2018

Tutt Andrew, Tovey Holly, Cheang Maggie Chon U, Kernaghan Sarah, Kilburn Lucy, Gazinska Patrycja, Owen Julie, Abraham Jacinta, Barrett Sophie, Barrett-Lee Peter, Brown Robert, Chan Stephen, Dowsett Mitchell, Flanagan James M, Fox Lisa, Grigoriadis Anita, Gutin Alexander, Harper-Wynne Catherine, Hatton Matthew Q, Hoadley Katherine A, Parikh Jyoti, Parker Peter, Perou Charles M, Roylance Rebecca, Shah Vandna, Shaw Adam, Smith Ian E, Timms Kirsten M, Wardley Andrew M, Wilson Gregory, Gillett Cheryl, Lanchbury Jerry S, Ashworth Alan, Rahman Nazneen, Harries Mark, Ellis Paul, Pinder Sarah E, Bliss Judith M

Abstract excerpt

Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs DNA lesions caused by platinum agents and PARP inhibitors. Triple-negative breast cancers (TNBCs) harbor subpopulations with BRCA1/2 mutations, hypothesized to be especially platinum-sensitive....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Carboplatin

Share to Homologous Recombination

Share to Mutation

Share to Progression-Free Survival

Share to Treatment Outcome

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 29713086
DOI: 10.1038/s41591-018-0009-7
PMCID: PMC6372067

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.PMID 29713086Read ↗

Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial.Semantic proximity Read ↗

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.Semantic proximity Read ↗

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightnessSemantic proximity Read ↗

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 TrialSemantic proximity Read ↗

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapySemantic proximity Read ↗

Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.Semantic proximity Read ↗

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.Semantic proximity Read ↗

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.Semantic proximity Read ↗

Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.Semantic proximity Read ↗

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes.Semantic proximity Read ↗

Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell LinesSemantic proximity Read ↗

Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.